Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17937554 | 0.87 | BTK (0.46) | BTK | |
| SCHEMBL24966693 | 0.86 | BTK (0.48) | BTK | |
| SCHEMBL29836881 | 0.84 | BTK (0.44) | BTK | |
| SCHEMBL17958856 | 0.84 | BTK (0.44) | BTK | |
| SCHEMBL29836863 | 0.84 | BTK (0.44) | BTK | |
| SCHEMBL31077836 | 0.83 | BTK (0.62) | BTK | |
| SCHEMBL1725249 | 0.83 | BTK (0.62) | BTK | |
| SCHEMBL17971496 | 0.82 | BTK (0.49) | BTK | |
| SCHEMBL17958862 | 0.77 | BTK (0.45) | BTK | |
| SCHEMBL14696256 | 0.76 | BTK (0.44) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221991-A1 | NOVEL TRIAZINE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2016-08-04 | — | — | US | disclosed |
| EP-3048102-A1 | NOVEL TRIAZINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20150175608-A1 | NOVEL 4-SUBSTITUTED 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175608-A1 | NOVEL 4-SUBSTITUTED 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | SARS1, HRH4, H1-4 | BTK 1813/4885 |
| US-20160221991-A1 | NOVEL TRIAZINE DERIVATIVE | BAZ2A, BAZ2B, DOT1L | BTK 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.